Scientists have found independent adverse factors that affect the efficacy of CAR-T

The team of Professor Zhai Zhimin of Anhui Medical University's Second Affiliated Hospital conducted clinical studies on the topic of "CAR-T Treatment of Leukemia" and reported for the first time that extra-bone marrow aggression and highly inhibitory T-cells were independent adverse factors affecting the efficacy of CAR-T treatment. Research shows that the domestic CAR-T treatment technology can be comparable to the level of developed countries in Europe and the United States. The results were published in nature-newsletter.
new gene therapy CAR-T, is a new form of malignant tumor treatment developed in recent years, that is, through genetic modification, T-cells into "living drugs", to curb malignant tumors opened a new door.
team screened 51 patients with relapsed acute leukemia from 72 patients who were interested in car-T cell therapy. Among them, 47 patients between the ages of 3 and 72 were successfully evaluated for CD19 CAR-T cell infusion and efficacy. In the current clinical studies on CD19 CAR-T cell therapy at home and abroad, the research risk and difficulty are greatly increased due to the large number of cases included, the largest age span of patients, and the highest proportion of patients with myeloid lesions.
The results of careful treatment, observation follow-up and systematic analysis of patients in the group in the past 5 years showed that the total remission rate was 81%, and the total survival rate and recurrence rate of 1 year were 53.0% and 45.0%, respectively, which was similar to the results of other medical research centers in Europe and the United States. In particular, the occurrence of serious adverse reactions above level 4 is only 6.4%, while reports in Europe and the United States show that the general rate is about 30%. This suggests that CD19 CAR-T cells designed and manufactured in China are not only effective, but also safer in the treatment process.
The results further explore the effects of patient factors on CAR-T treatment, and it is of great significance to further improve the quality of CAR-T cells, optimize treatment mode and promote the transformation of CAR-T treatment into clinical application in China. (Source: Gui Yun'an, China Science Journal)
relevant paper information: